Celiac Disease vs Gluten Sensitivity: Testing, Diagnosis, and Key Differences

Confusion between celiac disease and non-celiac gluten sensitivity (NCGS) is widespread, partly because their symptoms overlap substantially, and partly because both seem to respond to a gluten-free diet. But the mechanisms, diagnostic workup, long-term risks, and management requirements are very different. Treating NCGS as if it were celiac (or vice versa) leads either to unnecessary dietary restriction or to missed diagnosis of a serious autoimmune condition.

There is also a third category: wheat allergy, which involves IgE-mediated immune responses to wheat proteins and has its own distinct presentation, diagnostic test, and management approach. This article covers all three.

Celiac Disease: What It Actually Is

Celiac disease is a T-cell-mediated autoimmune condition triggered by dietary gluten (specifically the gliadin component of gluten in wheat, hordein in barley, and secalin in rye). In genetically susceptible individuals, gliadin peptides crossing the intestinal epithelium trigger an immune response that attacks the intestinal villi, the finger-like projections responsible for nutrient absorption in the small intestine.

The result is villous atrophy, crypt hyperplasia, and increased intraepithelial lymphocytes, a pattern characteristic of celiac disease and classified by the Marsh scoring system. Villous atrophy reduces the absorptive surface of the small intestine by up to 90% in severe cases, causing malabsorption of fat, fat-soluble vitamins, iron, calcium, and folate.

Celiac affects approximately 1% of the general population in most Western countries, though up to 80% of cases remain undiagnosed. The condition has a strong genetic component: 95% of celiac patients carry HLA-DQ2 (most common) or HLA-DQ8 alleles, though these alleles alone are not sufficient (approximately 30% of the general population carries them without developing celiac).

Non-Celiac Gluten Sensitivity: What We Know and Don’t Know

NCGS refers to a condition in which individuals without celiac disease or wheat allergy experience gastrointestinal and/or extraintestinal symptoms that improve on a gluten-free diet and recur when gluten is reintroduced. By definition, NCGS has no biomarker. There is no blood test, no biopsy finding, and no genetic marker that diagnoses it.

The condition became widely discussed after a 2011 RCT by Biesiekierski et al. in The American Journal of Gastroenterology (n=34) appeared to demonstrate that gluten caused symptoms in non-celiac individuals. But the same research group published a follow-up in 2013, in Gastroenterology (n=37), that significantly complicated this conclusion.

The Biesiekierski 2013 Re-challenge Trial

In the 2013 study, participants who self-identified as gluten-sensitive were placed on a low-FODMAP diet (eliminating fermentable carbohydrates including fructans, the primary FODMAP in wheat) and then randomized in a double-blind crossover design to receive high-gluten, low-gluten, or whey protein (control) diets. All three groups experienced symptom improvement on the low-FODMAP baseline, and none showed a statistically significant difference in GI symptoms when gluten was added back in.